Literature DB >> 32701511

Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children.

Pui Y Lee1, Megan Day-Lewis1, Lauren A Henderson1, Kevin G Friedman2, Jeffrey Lo1, Jordan E Roberts1, Mindy S Lo1, Craig D Platt1, Janet Chou1, Kacie J Hoyt1, Annette L Baker2, Tina M Banzon1, Margaret H Chang1, Ezra Cohen1,3, Sarah D de Ferranti2, Audrey Dionne2, Saddiq Habiballah1, Olha Halyabar1, Jonathan S Hausmann1,4, Melissa M Hazen1, Erin Janssen1, Esra Meidan1, Ryan W Nelson1, Alan A Nguyen1, Robert P Sundel1, Fatma Dedeoglu1, Peter A Nigrovic1,5, Jane W Newburger2, Mary Beth F Son1.   

Abstract

BACKGROUNDPediatric SARS-CoV-2 infection can be complicated by a dangerous hyperinflammatory condition termed multisystem inflammatory syndrome in children (MIS-C). The clinical and immunologic spectrum of MIS-C and its relationship to other inflammatory conditions of childhood have not been studied in detail.METHODSWe retrospectively studied confirmed cases of MIS-C at our institution from March to June 2020. The clinical characteristics, laboratory studies, and treatment response were collected. Data were compared with historic cohorts of Kawasaki disease (KD) and macrophage activation syndrome (MAS).RESULTSTwenty-eight patients fulfilled the case definition of MIS-C. Median age at presentation was 9 years (range: 1 month to 17 years); 50% of patients had preexisting conditions. All patients had laboratory confirmation of SARS-CoV-2 infection. Seventeen patients (61%) required intensive care, including 7 patients (25%) who required inotrope support. Seven patients (25%) met criteria for complete or incomplete KD, and coronary abnormalities were found in 6 cases. Lymphopenia, thrombocytopenia, and elevation in inflammatory markers, D-dimer, B-type natriuretic peptide, IL-6, and IL-10 levels were common but not ubiquitous. Cytopenias distinguished MIS-C from KD and the degree of hyperferritinemia and pattern of cytokine production differed between MIS-C and MAS. Immunomodulatory therapy given to patients with MIS-C included intravenous immune globulin (IVIG) (71%), corticosteroids (61%), and anakinra (18%). Clinical and laboratory improvement were observed in all cases, including 6 cases that did not require immunomodulatory therapy. No mortality was recorded in this cohort.CONCLUSIONMIS-C encompasses a broad phenotypic spectrum with clinical and laboratory features distinct from KD and MAS.FUNDINGThis work was supported by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases; the National Institute of Allergy and Infectious Diseases; Rheumatology Research Foundation Investigator Awards and Medical Education Award; Boston Children's Hospital Faculty Career Development Awards; the McCance Family Foundation; and the Samara Jan Turkel Center.

Entities:  

Keywords:  COVID-19; Clinical practice; Immunology

Mesh:

Substances:

Year:  2020        PMID: 32701511      PMCID: PMC7598077          DOI: 10.1172/JCI141113

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs.

Authors:  Rishi K Wadhera; Priya Wadhera; Prakriti Gaba; Jose F Figueroa; Karen E Joynt Maddox; Robert W Yeh; Changyu Shen
Journal:  JAMA       Date:  2020-06-02       Impact factor: 56.272

2.  Gamma-globulin treatment of acute myocarditis in the pediatric population.

Authors:  N A Drucker; S D Colan; A B Lewis; A S Beiser; D L Wessel; M Takahashi; A L Baker; A R Perez-Atayde; J W Newburger
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

3.  Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease.

Authors:  John J Strouse; Clifford M Takemoto; Jeffrey R Keefer; Gregory J Kato; James F Casella
Journal:  Pediatr Blood Cancer       Date:  2008-05       Impact factor: 3.167

4.  Coagulation abnormalities and thrombosis in patients with COVID-19.

Authors:  Marcel Levi; Jecko Thachil; Toshiaki Iba; Jerrold H Levy
Journal:  Lancet Haematol       Date:  2020-05-11       Impact factor: 18.959

5.  Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease.

Authors:  Emanuele Pontali; Stefano Volpi; Giancarlo Antonucci; Marco Castellaneta; Davide Buzzi; Francesca Tricerri; Alessia Angelelli; Roberta Caorsi; Marcello Feasi; Francesca Calautti; Elio Castagnola; Gian Andrea Rollandi; Angelo Ravelli; Giovanni Cassola; Marco Gattorno
Journal:  J Allergy Clin Immunol       Date:  2020-05-11       Impact factor: 10.793

6.  Hyperinflammatory shock in children during COVID-19 pandemic.

Authors:  Shelley Riphagen; Xabier Gomez; Carmen Gonzalez-Martinez; Nick Wilkinson; Paraskevi Theocharis
Journal:  Lancet       Date:  2020-05-07       Impact factor: 79.321

7.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

8.  Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study.

Authors:  Julie Toubiana; Clément Poirault; Alice Corsia; Fanny Bajolle; Jacques Fourgeaud; François Angoulvant; Agathe Debray; Romain Basmaci; Elodie Salvador; Sandra Biscardi; Pierre Frange; Martin Chalumeau; Jean-Laurent Casanova; Jérémie F Cohen; Slimane Allali
Journal:  BMJ       Date:  2020-06-03

Review 9.  Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.

Authors:  Paola Toniati; Simone Piva; Marco Cattalini; Emirena Garrafa; Francesca Regola; Francesco Castelli; Franco Franceschini; Paolo Airò; Chiara Bazzani; Eva-Andrea Beindorf; Marialma Berlendis; Michela Bezzi; Nicola Bossini; Maurizio Castellano; Sergio Cattaneo; Ilaria Cavazzana; Giovanni-Battista Contessi; Massimo Crippa; Andrea Delbarba; Elena De Peri; Angela Faletti; Matteo Filippini; Matteo Filippini; Micol Frassi; Mario Gaggiotti; Roberto Gorla; Michael Lanspa; Silvia Lorenzotti; Rosa Marino; Roberto Maroldi; Marco Metra; Alberto Matteelli; Denise Modina; Giovanni Moioli; Giovanni Montani; Maria-Lorenza Muiesan; Silvia Odolini; Elena Peli; Silvia Pesenti; Maria-Chiara Pezzoli; Ilenia Pirola; Alessandro Pozzi; Alessandro Proto; Francesco-Antonio Rasulo; Giulia Renisi; Chiara Ricci; Damiano Rizzoni; Giuseppe Romanelli; Mara Rossi; Massimo Salvetti; Francesco Scolari; Liana Signorini; Marco Taglietti; Gabriele Tomasoni; Lina-Rachele Tomasoni; Fabio Turla; Alberto Valsecchi; Davide Zani; Francesco Zuccalà; Fiammetta Zunica; Emanuele Focà; Laura Andreoli; Nicola Latronico
Journal:  Autoimmun Rev       Date:  2020-05-03       Impact factor: 9.754

10.  SARS-CoV-2 Infection in Children.

Authors:  Xiaoxia Lu; Liqiong Zhang; Hui Du; Jingjing Zhang; Yuan Y Li; Jingyu Qu; Wenxin Zhang; Youjie Wang; Shuangshuang Bao; Ying Li; Chuansha Wu; Hongxiu Liu; Di Liu; Jianbo Shao; Xuehua Peng; Yonghong Yang; Zhisheng Liu; Yun Xiang; Furong Zhang; Rona M Silva; Kent E Pinkerton; Kunling Shen; Han Xiao; Shunqing Xu; Gary W K Wong
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

View more
  105 in total

1.  Cardiac markers of multisystem inflammatory syndrome in children (MIS-C) in COVID-19 patients: A meta-analysis.

Authors:  Yan Zhao; Jenil Patel; Ying Huang; Lijuan Yin; Lei Tang
Journal:  Am J Emerg Med       Date:  2021-05-18       Impact factor: 2.469

2.  The Trilogy of SARS-CoV-2 in Pediatrics (Part 2): Multisystem Inflammatory Syndrome in Children.

Authors:  Van L Tran; Sarah Parsons; Andrew Nuibe
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

3.  Similarities and differences between the immunopathogenesis of COVID-19-related pediatric multisystem inflammatory syndrome and Kawasaki disease.

Authors:  Ana Esteve-Sole; Jordi Anton; Rosa Maria Pino-Ramirez; Judith Sanchez-Manubens; Victoria Fumadó; Claudia Fortuny; María Rios-Barnes; Joan Sanchez-de-Toledo; Mónica Girona-Alarcón; Juan Manuel Mosquera; Silvia Ricart; Cristian Launes; Mariona Fernández de Sevilla; Cristina Jou; Carmen Muñoz-Almagro; Eva González-Roca; Andrea Vergara; Jorge Carrillo; Manel Juan; Daniel Cuadras; Antoni Noguera-Julian; Iolanda Jordan; Laia Alsina
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

4.  Is multisystem inflammatory syndrome in children on the Kawasaki syndrome spectrum?

Authors:  Rae Sm Yeung; Polly J Ferguson
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

5.  Socioeconomic and Racial and/or Ethnic Disparities in Multisystem Inflammatory Syndrome.

Authors:  Karina Javalkar; Victoria K Robson; Lukas Gaffney; Amy M Bohling; Puneeta Arya; Sarah Servattalab; Jordan E Roberts; Jeffrey I Campbell; Sepehr Sekhavat; Jane W Newburger; Sarah D de Ferranti; Annette L Baker; Pui Y Lee; Megan Day-Lewis; Emily Bucholz; Ryan Kobayashi; Mary Beth Son; Lauren A Henderson; John N Kheir; Kevin G Friedman; Audrey Dionne
Journal:  Pediatrics       Date:  2021-02-18       Impact factor: 7.124

6.  American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2.

Authors:  Lauren A Henderson; Scott W Canna; Kevin G Friedman; Mark Gorelik; Sivia K Lapidus; Hamid Bassiri; Edward M Behrens; Anne Ferris; Kate F Kernan; Grant S Schulert; Philip Seo; Mary Beth F Son; Adriana H Tremoulet; Rae S M Yeung; Amy S Mudano; Amy S Turner; David R Karp; Jay J Mehta
Journal:  Arthritis Rheumatol       Date:  2021-02-15       Impact factor: 10.995

7.  Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19.

Authors:  Laura A Vella; Josephine R Giles; Amy E Baxter; Derek A Oldridge; Caroline Diorio; Leticia Kuri-Cervantes; Cécile Alanio; M Betina Pampena; Jennifer E Wu; Zeyu Chen; Yinghui Jane Huang; Elizabeth M Anderson; Sigrid Gouma; Kevin O McNerney; Julie Chase; Chakkapong Burudpakdee; Jessica H Lee; Sokratis A Apostolidis; Alexander C Huang; Divij Mathew; Oliva Kuthuru; Eileen C Goodwin; Madison E Weirick; Marcus J Bolton; Claudia P Arevalo; Andre Ramos; C J Jasen; Peyton E Conrey; Samir Sayed; Heather M Giannini; Kurt D'Andrea; Nuala J Meyer; Edward M Behrens; Hamid Bassiri; Scott E Hensley; Sarah E Henrickson; David T Teachey; Michael R Betts; E John Wherry
Journal:  Sci Immunol       Date:  2021-03-02

Review 8.  Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents.

Authors:  Giorgio Costagliola; Erika Spada; Rita Consolini
Journal:  Pediatr Rheumatol Online J       Date:  2021-05-04       Impact factor: 3.054

Review 9.  PIMS-TS, the New Paediatric Systemic Inflammatory Disease Related to Previous Exposure to SARS-CoV-2 Infection-"Rheumatic Fever" of the 21st Century?

Authors:  Violetta Opoka-Winiarska; Ewelina Grywalska; Jacek Roliński
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

10.  Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study.

Authors:  Jackeline J Rodriguez-Smith; Emely L Verweyen; Gwendolyn M Clay; Ysabella M Esteban; Sarah R de Loizaga; Elizabeth Joy Baker; Thuy Do; Sanjeev Dhakal; Sean M Lang; Alexei A Grom; David Grier; Grant S Schulert
Journal:  Lancet Rheumatol       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.